Developmental lead (pb) exposure induces anxiety and depression-like behaviors via inhibiting the AMPK/ACSS2 pathway Authors: Mengqin Tao, Shu Ai, Xiaozhen Gu, Mengmeng Wang, Mingli Sun, Hui-Li Wang Published: 2026 ABSTRACT Environmental lead (Pb) exposure is a risk factor for anxiety and depression. Our previous study showed Pb-induced neurotoxicity involves dysregulated epigenetic modifiers, yet the role of acyl-CoA synthetase short-chain family member 2 (ACSS2)—a key regulator of histone acetylation—in these behaviors remains unclear. Beginning at gestational day 0 (GD 0, plug day) and continuing through weaning (PND 21), C57BL/6 J dams received 100 ppm Pb in drinking water, exposing offspring indirectly via placenta and milk; after weaning, offspring received the same Pb solution directly from drinking water until PND 60. Behavioral tests revealed developmental Pb exposure induced anxiety and depression-like behaviors, accompanied by neuronal morphological damage in the medial prefrontal cortex (mPFC). Mechanistically, Pb inhibited AMP-activated protein kinase (AMPK) activity, suppressing ACSS2 expression and its nuclear translocation, which reduced nuclear acetyl-CoA and histone H3 lysine 9 acetylation (H3K9ac). The AMPK agonist 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) restored ACSS2 expression and phosphorylation, confirming AMPK as its upstream regulator. These epigenetic changes accompanied downregulated synaptic molecules (GluN2A, VGLUT1, PSD-95). ACSS2 restoration via D-mannose supplementation rescued synaptic protein loss, reversed neuronal structural impairments, and alleviated Pb-induced emotional deficits. Our findings identify the AMPK/ACSS2 pathway as a core regulator of Pb-induced affective disorders, whereby its inhibition epigenetically silences synaptic molecular expression, and nominates ACSS2 augmentation as a viable therapeutic strategy. Introduction Anxiety and depression are one of the most common mental disorders worldwide, imposing a substantial burden on both individual well-being and societal welfare. According to China's first National Epidemiological Survey on Adult Mental Disorders, the prevalence of depression steadily increased from 2012 to 2015, with reported 12-month and lifetime prevalence rates of 2.1% and 3.4%, respectively (Kong et al., 2023). Similarly, the prevalence of anxiety disorders in China was reported at 4.98% in 2017, a figure significantly exceeding those from the 1980s and 1990s (Lu et al., 2021; Huang et al., 2019). The World Health Organization (WHO) reports that depression affects more than 350 million individuals worldwide, constituting over 4% of the global population (Yin et al., 2024; Thapar et al., 2022; Wang et al., n.d.). According to WHO projections, depression is anticipated to emerge as the primary contributor to the worldwide disease burden by 2030 (Zhao et al., 2024). These disorders severely impair quality of life and impose significant socio-economic costs, highlighting the urgent need to elucidate their neurobiological underpinnings and develop targeted therapies. The etiology of depression is multifactorial, involving interactions among genetic, neurobiological, environmental, and epigenetic factors. Epidemiological studies indicate that children of individuals with major depressive disorder (MDD) have a 35%–40% risk of developing the condition in early adulthood, approximately twice the risk in the general population (Chen et al., 2025; Ni et al., 2023). While heritability is estimated at around 37% (Kendler et al., 2018), the core pathological basis of depression is widely considered to be a disruption of neural plasticity—encompassing both synaptic and structural plasticity—in which the downregulation of brain-derived neurotrophic factor (BDNF) is a key event (Bhandari et al., 2018). Epigenetic mechanisms, which modulate gene activity independent of DNA sequence changes, function as a key bridge linking environmental exposures to genetic susceptibility in MDD (Marx et al., 2023). Pb is a pervasive environmental neurotoxicant that enters the human body through air, water, and food (Gundacker et al., 2021; Mason et al., 2014; Senut et al., 2012). The developing brain is especially vulnerable; children absorb Pb up to five times more efficiently than adults, with ∼70% accumulating in brain tissue due to an immature blood–brain barrier (Pfadenhauer et al., 2014; Xu et al., n.d.). Pb exposure is an established risk factor for multiple central nervous system disorders, including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and attention deficit/hyperactivity disorder (ADHD) (Duan et al., 2021; Althobaiti, 2025). Epidemiological studies have also linked Pb exposure to anxiety and depression (Nouri et al., 2020), findings our group recapitulated in a chronic Pb-exposed mouse model (Zhou et al., 2023). Despite this evidence, the molecular mechanisms driving Pb-induced emotional dysfunction remain incompletely understood. In recent years, epigenetic mechanisms have emerged as a critical interface linking environmental factors to gene expression and have been implicated in the neurotoxicity induced by various environmental toxicants. Histone acetylation, as an epigenetic regulatory mechanism, provides a compelling framework for explaining these observations. Epigenetic regulation via histone acetylation offers a compelling explanatory framework. In MDD patients, elevated levels of histone deacetylases (HDAC2, 3, 4) in the prefrontal cortex and hippocampus correlate with reduced acetylation of H3K9 and H3K27 and transcriptional repression of neuroplasticity-related genes such as BDNF and cAMP response element-binding protein (CREB) (). Conversely, HDAC inhibitors such as metformin produce antidepressant effects in animal models by restoring global histone acetylation (Huang et al., 2021; Ortega et al., 2022). These findings implicate histone acetylation deficits in mood disorders, yet the upstream regulators of this epigenetic imbalance—particularly in the context of Pb neurotoxicity—are not fully characterized. Histone acetylation dynamics depend on the availability of acetyl-CoA (Korten et al., 2025; Wang et al., 2024), which is partly generated by the acyl-CoA synthetase short-chain family (ACSS). ACSS2, an isoform localized in both cytoplasm and nucleus, is particularly important for local acetyl-CoA synthesis and histone acetylation (Wang et al., 2025; Ling et al., 2022; Li et al., 2017a). Under metabolic stress, AMPK phosphorylates ACSS2 and promotes its nuclear translocation, where it converts acetate—potentially recycled from deacetylated histones—into acetyl-CoA to fuel transcription of specific genes (Chen et al., 2024; Li et al., 2021a). We examined AMPK-ACSS2 signaling pathway in Pb-induced anxiety and depression-like behaviors in mice, with a specific focus on the associated epigenetic mechanisms involving histone acetylation, systematically validated this hypothesis in vivo and in vitro. Our results demonstrated that pharmacological activation of ACSS2 with D-mannose effectively ameliorates Pb-induced behavioral deficits and restores related molecular alterations. These findings uncover a novel mechanism of Pb neurotoxicity and identify ACSS2 as a potential therapeutic target for environmental stress-related neuropsychiatric disorders. Materials and methods Materials Pb acetate was obtained from Sinopharm Chemical Reagent Co., Ltd. in Beijing, China. D-Mannose (HY-N0379R) and AICAR (HY-13417) were obtained from MedChemExpress (Monmouth Junction, NJ, USA). Nerve Growth Factor (NGF) (13257–019) was sourced from Gibco (Thermo Fisher Scientific, Waltham, MA, USA). The Acetyl-CoA (A-CoA) Enzyme-Linked Immunosorbent Assay (ELISA) Kit (E-EL-0125) was purchased from Elabscience Biotechnology Co., Ltd. (Wuhan, China). The Cell Counting Kit-8 (CCK-8; BS350B) was from Biosharp (Hefei, China). Poly-l-lysine (PLL; P4707) was from Sigma-Aldrich. The following primary antibodies were used: anti-H3K9ac (29133–1-AP; Proteintech, Rosemont, IL, USA), anti-ACSS2 (16087–1-AP; Proteintech), anti-ACSS2 (Phospho-Ser659) (58,003; Signalway Antibody, College Park, MD, USA), anti-ACSS1 (17138–1-AP; Proteintech), anti-AMPK (10929–2-AP; Proteintech), anti-GluN2 A (glutamate receptor ionotropic, NMDA 2 A; 4205; Cell Signaling Technology, Danvers, MA, USA), anti-PSD95 (postsynaptic density protein 95; 3409; Cell Signaling Technology), and anti-VGLUT1 (vesicular glutamate transporter 1; 98,199; Cell Signaling Technology). Animals Animals and housing conditions Female C57BL/6 J mice at eleven weeks of age and male breeder mice (C57BL/6 J, 10–12 weeks old) were obtained from Hangzhou Ziyuan Laboratory Animal Technology Co., Ltd. A total of 20 females and 10 males were used for breeding. The mice were of the C57BL/6 J substrain (Jackson lineage), as confirmed by the supplier. All animal experiments were conducted in accordance with the standards approved by the Animal Use and Care Committee of Hefei University of Technology (HFUT20250110002M). The approval standards of Hefei University of Technology strictly follow the eighth edition of the Guide for the Care and Use of Laboratory Animals published by the National Research Council of the National Academy of Sciences of the United States. Additionally, this study complies with the Animal Research: Reporting In Vivo Experiments (ARRIVE) guidelines. The animals were maintained under controlled environmental conditions, with a temperature of 23 ± 2 °C, humidity at 55 ± 5%, and a 12-h light/dark cycle. Food and water were provided ad libitum. All animals were fed a standard chow diet (Keao Xieli, Beijing, China; product code: XTC60) throughout the study. Developmental pb exposure paradigm For mating, female mice were paired with fertile male counterparts overnight at a female-to-male ratio of 2:1 (two females per one male). Successful mating was verified the next morning by identifying a vaginal plug, and the day of plug detection was designated as gestational day 0 (GD 0, plug day). It should be noted that, physiologically, pregnancy is considered to begin at implantation (∼GD 4.5 in mice); however, Pb exposure was started at GD 0 to ensure coverage of the entire peri-implantation period. All 20 females became pregnant after mating. Pregnant dams were randomly assigned to four experimental groups (n = 5 dams per group): control (Ctrl), Pb-exposed (Pb), Pb-exposed with D-mannose treatment (Pb + D-Man), and D-mannose treatment alone (D-Man). Pb exposure was initiated at GD 0 and continued through two distinct phases. During the first phase (GD 0 to PND 21), dams in the Pb and Pb + D-Man groups received drinking water supplemented with 100 ppm Pb, delivered as Pb acetate trihydrate (Guo Yao, Shanghai, China), and offspring were exposed to Pb indirectly via transplacental transfer during gestation and through maternal milk during lactation. The control and D-Man groups received double-distilled water (ddH₂O) throughout this period. Water consumption was monitored weekly during gestation and lactation, and no significant differences in fluid intake were observed among groups (Supplementary Table S1). During the second phase (PND 21 to PND 60), after weaning and separation from dams, offspring in the Pb and Pb + D-Man groups continued to receive drinking water containing 100 ppm Pb ad libitum, while offspring in the Ctrl and D-Man groups received ddH₂O, resulting in direct Pb exposure throughout the post-weaning period. Food and water consumption were not systematically measured during the post-weaning period, as the primary focus was on behavioral and molecular outcomes at PND 60. The date of delivery was recorded for each dam. No maternal deaths occurred in any group. Delivery occurred on GD 19–20 in all dams, with no significant difference among groups. Litter sizes at birth varied, ranging from 4 to 6 pups per litter, with a roughly balanced male-to-female ratio across litters (no culling performed). No stillbirths, morphological abnormalities, or significant differences in litter size or sex ratio were observed among groups. After weaning on PND 21, offspring were housed in same-sex groups (3–4 mice per cage) with ad libitum access to food and water (Pb-containing water for Pb and Pb + D-Man groups, ddH₂O for Ctrl and D-Man groups). No offspring mortality occurred during the post-weaning period. Offspring body weight was monitored weekly from PND 7 to PND 81. Body weight measurements were initiated at PND 7 rather than at birth to minimize handling-induced stress in pups (neonatal mice have poor thermoregulation and frequent handling can lead to hypothermia), to prevent maternal anxiety, neglect, or cannibalism caused by excessive early-life disturbance, and to reduce the risk of bacterial contamination, as neonatal mice are highly susceptible to infection during the first week of life. No significant differences in weight gain trajectories were detected among groups (Supplementary Fig. S1). Intervention and behavioral testing For the D-mannose rescue experiment, pregnant dams were randomly assigned to four experimental groups as described in Section 2.2.2: Ctrl, Pb, Pb + D-Man, and D-Man (n = 5 dams per group). Litter sizes at birth ranged from 4 to 6 pups, with a roughly balanced male-to-female ratio across litters. Behavioral tests were conducted at postnatal day 60 (PND 60). A two-day interval was allowed between successive tests to minimize carryover effects, and the tests were performed in the following order: elevated plus maze (EPM), tail suspension test (TST), and forced swimming test (FST). For behavioral assessments, 10 offspring per group (n = 10; 5 males and 5 females) were randomly selected from the four experimental groups. These offspring were derived from the 5 litters per group, with no more than one pup per sex per litter (typically one male and one female per litter) to minimize litter effects. Thus, the individual offspring served as the experimental unit for behavioral analyses. For molecular analyses (western blotting and immunohistochemistry), 6 offspring per group (n = 6) were randomly selected from the 5 litters, with balanced representation across litters. For histological staining (hematoxylin-eosin and Nissl), 3 offspring per group (n = 3) were randomly selected from the 5 litters. All offspring were euthanized at PND 81 by decapitation under deep anesthesia induced by intraperitoneal injection of sodium pentobarbital (6 mg/mL in saline). The study included offspring of both sexes. For behavioral tests, exactly 5 males and 5 females were selected per group; for molecular and histological analyses, the sex ratio was approximately balanced. Preliminary analysis revealed no significant sex-dependent effects of Pb exposure on the measured outcomes; therefore, data from male and female offspring were pooled for statistical analysis. D-mannose supplementation To investigate the therapeutic potential of ACSS2 activation, four experimental groups were established as described in Section 2.2.2: control (Ctrl), Pb-exposed (Pb), Pb-exposed with D-mannose treatment (Pb + D-Man), and D-mannose treatment alone (D-Man) (n = 5 dams per group). Pregnant dams were randomly assigned to the four groups. Offspring from the same litter were not split across treatment groups (i.e., litters were not split). Thus, all offspring from a given litter were assigned to the same treatment condition. D-mannose (HY-N0379R, MedChemExpress, USA), a naturally occurring monosaccharide, was dissolved in sterile water at a concentration of 20% (w/v; 200 mg/mL) and administered via daily oral gavage at a dose of 2 g/kg body weight (volume: 0.2 mL per mouse, approximately 10 mL/kg) to C57BL/6 J mice for two weeks (from PND 45 to PND 59). The dose was selected based on a previous study showing that D-mannose at 2 g/kg effectively activates ACSS2 and produces antidepressant-like effects in mice (Chen et al., 2023). The treatment window (PND 45–59) was chosen to cover the two-week period immediately before behavioral testing (PND 60) to assess the acute effects of ACSS2 activation on anxiety and depression-like behaviors. All treatments were administered between 9:00 and 10:00 AM daily to minimize circadian variability. The Pb + D-Man and D-Man groups received D-mannose solution, while the Ctrl and Pb groups received an equivalent volume of sterile water following the same schedule. The D-mannose-only group (D-Man) was included to exclude potential non-specific effects of the compound. The Pb exposure paradigm was maintained as described in Section 2.2.2, with Pb exposure continuing throughout the treatment period. All offspring were maintained on their respective treatments until euthanasia under deep anesthesia as described in Section 2.2.3. Behavioral testing Elevated plus maze test (EPM) The EPM was composed of two open arms (8 cm × 34 cm) and two identically sized enclosed arms, positioned opposite one another and joined by a central square area (8 cm × 8 cm). The whole structure was raised 50 cm above ground level. At the start of each test, a mouse was positioned at the center of the maze, oriented toward an open arm, and permitted to move unrestrictedly throughout the apparatus for a 7-min period. A camera mounted on the ceiling captured all behavioral activities. The sequence of testing was systematically varied across experimental groups to reduce odor interference, and the apparatus was carefully wiped with 75% ethanol following every session to eliminate any residual biological material. Using the ANY-maze video tracking software, the recordings were processed to measure both the frequency of open arm entries and the cumulative duration spent in the open sections. Forced swimming test (FST) The FST involved placing each mouse individually into a 2 L transparent glass cylinder containing fresh water at a depth of 15 cm (around 1.5 L volume). The water temperature was consistently held at 22 ± 1 °C. Every test session continued for a duration of 6 min and was recorded on video. An automated analysis of the immobility time, characterized by passive floating with only essential movements to maintain the head above water, was performed for the last four min of the trial using the ANY-maze system. Tail suspension test (TST) In the TST, each mouse was secured by its tail with adhesive tape to a horizontal bar, ensuring the head was positioned about 50 cm above the base. Behavioral sessions were recorded on video for a duration of 6 min. Using the ANY-maze video tracking system, the cumulative duration of immobility was automatically measured. A mouse was considered immobile when it hung passively without exhibiting any active limb or body movements. Histopathological analysis Following behavioral tests, mice were anesthetized by intraperitoneal injection of sodium pentobarbital (6 mg/mL in saline) and transcardially perfused with ice-cold phosphate-buffered saline (PBS) followed by 4% paraformaldehyde (PFA) in PBS. Brain tissues were carefully dissected and post-fixed in 4% PFA at 4 °C for 24 h, then dehydrated through a graded sucrose series (20% and 30% in PBS) until the tissues sank to the bottom. Tissue samples were then embedded in paraffin and sectioned into 5 μm thick coronal sections using a microtome. Sections were dewaxed, rehydrated, and subjected to hematoxylin-eosin (HE) staining and Nissl staining. The morphology of the mPFC and its neurons was observed and analyzed under a light microscope. Cell culture The PC-12 cells employed in this study were sourced from the Chinese Academy of Sciences Cell Bank. These rat adrenal medullary chromaffin tumor cells exhibit general characteristics of neural cells. PC-12 cells are a well-established neuronal model for studying neurotoxicity. Upon NGF stimulation, they differentiate into neuron-like cells and have been extensively used to investigate Pb-induced neurotoxicity, including cytotoxicity, oxidative stress, and alterations in neurotransmitter levels (Sanders et al., 2015; Zhang et al., 2022).The cells were categorized as undifferentiated (for neurite outgrowth observation) and highly differentiated (for RNA/protein extraction). PC-12 cells lines were maintained in complete medium consisting of Dulbecco's Modified Eagle Medium (DMEM, Keygen Biotech) and 10% fetal bovine serum (FBS, Evergreen). All cultures were incubated at 37 °C in a humidified chamber with 5% CO₂. PC-12 cells were seeded into 6-well plates. After 24 h of culture, cells were exposed to 5 μM Pb and treated with 1 mM D-mannose for 48 h. Cell viability assay PC-12 cell viability was assessed using the Cell Counting Kit-8 (CCK-8, BS350B, Biosharp, China) according to the manufacturer's instructions. Cells were seeded in 96-well plates at a density of 5 × 103 cells per well in 100 μL of complete medium and cultured overnight at 37 °C with 5% CO₂. After 24 h, cells were exposed to Pb at various concentrations (0, 1, 2.5, 5, 10, and 20 μM) for 48 h. Following treatment, 10 μL of CCK-8 solution was added to each well, and the plates were incubated at 37 °C for 2 h. Absorbance was measured at 450 nm using a microplate reader (BioTek, USA). Wells containing only culture medium and CCK-8 solution without cells were used as blank controls. All experiments were performed in triplicate with at least six replicate wells per concentration. Neurite outgrowth assay To evaluate neuronal process growth, this experiment employed undifferentiated PC12 cells cultured on poly-l-lysine (PLL)-coated glass slides, subsequently inducing their differentiation. First, the slides were sequentially placed in distilled water and anhydrous ethanol for ultrasonic cleaning three times each, thoroughly removing impurities. Following sterilization, they were set aside for later use. Subsequently, slides were coated with PLL solution within a laminar flow hood and incubated at 37 °C for 12 h. Following coating, slides were rinsed with sterile water, seeded with undifferentiated PC-12 cells, and cultured in proliferation medium for 24 h. Subsequently, the medium was replaced with differentiation medium containing 50 ng/mL nerve growth factor (NGF) and Pb for a further 5 days of culture, with a 50% medium change performed every 24 h. Following the culture period, cell morphology was observed under a fluorescence microscope and images were captured. ImageJ software was employed to quantitatively analyze the total length of cellular processes and the number of primary and secondary branches. Protein extraction and western blotting Protein extracts from mPFC tissues or PC-12 cells were prepared using ice-cold RIPA lysis buffer with 1 mM PMSF. After centrifugation at 12,000 ×g (10 min, 4 °C) to remove debris, protein concentrations in the supernatants were determined by BCA assay according to kit instructions (absorbance at 562 nm). Samples were normalized, mixed with 2 × Laemmli buffer, and boiled for 10 min. Proteins were separated by SDS-PAGE and transferred to PVDF membranes via wet transfer. Membranes were blocked with 5% skim milk (1 h, RT), incubated with primary antibodies overnight at 4 °C, washed with PBST, and developed with ECL substrate. Band detection was performed using a chemiluminescence imager, and quantitative analysis was conducted with ImageJ software. Immunohistochemistry After initial processing, cells were rinsed with ice-cold PBS and fixed with 4% paraformaldehyde on ice for 15 min. Permeabilization was achieved using 0.5% Triton X-100 prepared in PBS. To reduce nonspecific antibody interactions, the cells were treated with 10% goat serum for 1–2 h at room temperature, followed by three washes with PBS. The samples were then incubated with primary antibody diluted in PBS at 4 °C overnight. Subsequently, horseradish peroxidase-conjugated secondary antibody was applied and incubated for 1 h at 25 °C. Finally, nuclei were stained with DAPI, and an anti-fade mounting medium was applied prior to imaging. Fluorescence images were acquired using a Nikon microscope (Japan) and analyzed with ImageJ. The primary antibodies used in this study were as follows: anti-H3K9ac (29133–1-AP; Proteintech, 1:300), anti-ACSS2 (16087–1-AP; Proteintech, 1:300). Enzyme-linked immunosorbent assay (ELISA) Levels of acetyl-CoA in PC-12 cells, mouse mPFC tissue, and serum were determined using a commercial ELISA kit (Elabscience, Wuhan, China; catalog No. E-EL-0125) according to the manufacturer's protocol. The kit has a detection range of 0.31–20 ng/mL and a limit of detection of 0.19 ng/mL, with intra- and inter-assay coefficients of variation <10%. Sample preparation: Serum was obtained by centrifugation at 1000 ×g for 20 min. mPFC tissues were homogenized in PBS (1:9, w/v) and centrifuged at 5000 ×g for 10 min. PC-12 cells were lysed by freeze-thaw cycles and centrifuged at 1500 ×g for 10 min. All samples were diluted to fall within the linear range of the standard curve. Acetyl-CoA levels were expressed as ng/mL for all sample types. Statistical analysis All experimental results are expressed as the mean ± SEM. Normality was assessed using the Shapiro-Wilk test. All data met the assumptions of normality (p > 0.05), allowing the use of parametric tests. Statistical processing and graphical representation were conducted in GraphPad Prism 8 (GraphPad Software, USA). Differences between two groups were assessed by an unpaired two-tailed Student's t-test. Comparisons involving three or more groups were made using one-way ANOVA. For two-factor experiments (e.g., Pb exposure × D-mannose treatment), data were analyzed by two-way ANOVA followed by Tukey's multiple comparisons test. In this developmental toxicity study, the dam was considered the experimental unit for exposure (n = 5 dams per group). For offspring-derived data, the experimental unit and sample size varied by endpoint. For behavioral tests, the individual offspring served as the experimental unit, with n = 10 offspring per group (5 males and 5 females, selected from 5 litters with one male and one female per litter). For molecular analyses (western blotting and immunohistochemistry), n = 6 offspring per group (randomly selected from 5 litters). For ELISA and histological staining (HE and Nissl), n = 3 offspring per group (randomly selected from 5 litters). For analyses involving only dams (e.g., water consumption), n = 5 dams per group. Sex was initially included as a variable in the statistical model. Preliminary analysis revealed no significant main effects of sex or interactions between sex and treatment (Pb exposure or D-mannose treatment) on the measured outcomes. Therefore, data from male and female offspring were pooled for final statistical analysis to increase statistical power. Statistical significance was defined as p < 0.05, with the following levels indicated: *p < 0.05, **p < 0.01, and ***p < 0.001. Results Developmental pb exposure induces anxiety and depression-like behaviors accompanied by neuronal damage in mPFC Mice were continuously exposed to Pb from GD 0 to PND 60. Behavioral tests were performed at PND 60 (Fig. 1A). In the EPM test, Pb-exposed mice exhibited a reduction in open arm entries (unpaired t-test: t (18) = 3.556, p < 0.01) and time spent in open arms (t (18) = 2.842, p < 0.05) compared to controls, indicating anxiety-like behavior (Fig. 1B-E). Similarly, immobility time was increased in Pb-treated mice in both the TST (t (18) = 9.068, p < 0.001) and FST (t (18) = 14.02, p < 0.001), suggesting depressive-like behaviors (Fig. 1F-I).Fig. 1Developmental pb exposure induces anxiety and depression-like behaviors in mice. A schematic diagram of the experimental design showing pb exposure from GD 0 (plug day) to PND 60 (see section 2.2 for details). B schematic of the EPM. C representative images of locomotor trajectories in the EPM for control and pb-exposed mice. D open arm entries in the EPM. E time spent in open arms in the EPM. F schematic diagram of the TST. G immobility time in the TST. H schematic diagram of the FST. I immobility time in the FST. Data are presented as mean ± SEM and analyzed using unpaired t-tests (*p < 0.05; **p < 0.01; ***p < 0.001; ns, p > 0.05). For behavioral tests, n = 10 offspring per group (5 males and 5 females, selected from 5 litters with one male and one female per litter).Fig. 1 Developmental pb exposure induces anxiety and depression-like behaviors in mice. A schematic diagram of the experimental design showing pb exposure from GD 0 (plug day) to PND 60 (see section 2.2 for details). B schematic of the EPM. C representative images of locomotor trajectories in the EPM for control and pb-exposed mice. D open arm entries in the EPM. E time spent in open arms in the EPM. F schematic diagram of the TST. G immobility time in the TST. H schematic diagram of the FST. I immobility time in the FST. Data are presented as mean ± SEM and analyzed using unpaired t-tests (*p < 0.05; **p < 0.01; ***p < 0.001; ns, p > 0.05). For behavioral tests, n = 10 offspring per group (5 males and 5 females, selected from 5 litters with one male and one female per litter). Regarding neuronal morphology, HE staining revealed disordered neuronal arrangement, cell swelling, nuclear pyknosis, and vacuoles in the Pb-exposed group, whereas the Ctrl group showed compact and orderly structure (Fig. 2A). Consistently, Nissl staining showed a reduction in Nissl bodies and fewer healthy neurons in the Pb group (Fig. 2B).Fig. 2Pb exposure induces neuronal morphological damage in the mPFC.Representative images of HE staining (A) and Nissl staining (B) in the mPFC. Scale bar = 20 μm. Images are representative of n = 3 offspring per group (randomly selected from 5 litters).Fig. 2 Pb exposure induces neuronal morphological damage in the mPFC. Representative images of HE staining (A) and Nissl staining (B) in the mPFC. Scale bar = 20 μm. Images are representative of n = 3 offspring per group (randomly selected from 5 litters). Augmentation of ACSS2 expression improves behavioral abnormalities in pb-exposed mice Western blot analysis revealed a reduction in H3K9ac in Pb-exposed mice compared to controls (t (10) = 3.844, p < 0.01) (Fig. 3A). Consistently, acetyl-CoA levels were decreased in both the mPFC (t (4) = 10.05, p < 0.001) and serum (t (10) = 7.53, p < 0.01) of Pb-exposed mice (Fig. S3A, B).Fig. 3Augmentation of ACSS2 expression improves behavioral abnormalities in pb-exposed mice. A-C representative western blot images and quantitative analysis of H3K9ac, ACSS2, and p-ACSS2 in the mPFC. D—F representative western blot images and quantitative analysis of ACSS2, p-ACSS2, and H3K9ac in the mPFC after D-mannose treatment. G representative images of EPM locomotor trajectories across four mouse groups. H—I open arm entries and time spent in open arms during EPM. J schematic of TST. K schematic of FST. L immobility time in TST. M immobility time in FST. N HE staining of mPFC neurons. O Nissl staining of mPFC neurons. Scale bar = 20 μm. Sample sizes: For western blot, n = 6 offspring per group; for behavioral tests, n = 10 offspring per group (5 males and 5 females, one male and one female per litter from 5 litters); for histology, n = 3 offspring per group. Data are presented as mean ± SEM. Two-way ANOVA with Tukey's test was used for four-group comparisons; unpaired t-test was used for two-group comparisons. Ctrl: No pb, sterile water; pb: Pb, sterile water; pb + D-man: Pb, D-mannose; D-man: No pb, D-mannose. (*p < 0.05; **p < 0.01; ***p < 0.001; ns, p > 0.05).Fig. 3 Augmentation of ACSS2 expression improves behavioral abnormalities in pb-exposed mice. A-C representative western blot images and quantitative analysis of H3K9ac, ACSS2, and p-ACSS2 in the mPFC. D—F representative western blot images and quantitative analysis of ACSS2, p-ACSS2, and H3K9ac in the mPFC after D-mannose treatment. G representative images of EPM locomotor trajectories across four mouse groups. H—I open arm entries and time spent in open arms during EPM. J schematic of TST. K schematic of FST. L immobility time in TST. M immobility time in FST. N HE staining of mPFC neurons. O Nissl staining of mPFC neurons. Scale bar = 20 μm. Sample sizes: For western blot, n = 6 offspring per group; for behavioral tests, n = 10 offspring per group (5 males and 5 females, one male and one female per litter from 5 litters); for histology, n = 3 offspring per group. Data are presented as mean ± SEM. Two-way ANOVA with Tukey's test was used for four-group comparisons; unpaired t-test was used for two-group comparisons. Ctrl: No pb, sterile water; pb: Pb, sterile water; pb + D-man: Pb, D-mannose; D-man: No pb, D-mannose. (*p < 0.05; **p < 0.01; ***p < 0.001; ns, p > 0.05). We next examined ACSS1 and ACSS2 expression. ACSS1 protein levels showed no significant difference between Pb and Ctrl groups in the mPFC (t (10) = 1.343, p > 0.05) (Fig. S2A). In contrast, ACSS2 protein levels were downregulated in the mPFC of Pb-exposed mice (t (10) = 2.352, p < 0.05) (Fig. 3B). Corresponding to the total protein levels, we detected a marked decline in the phosphorylated, the active form of ACSS2 (p-ACSS2 Ser659) within the mice mPFC in vivo (t (10) = 3.143, p < 0.05) (Fig. 3C). Notably, ACSS2 expression in the mice hippocampus remained unaltered (t (10) = 1.110, p > 0.05) (Fig. S2B). A rescue experiment was performed using the ACSS2 agonist D-mannose (Chen et al., 2023). Four experimental groups were established: Ctrl, Pb, Pb + D-mannose and D-mannose. Beginning at PND 45, Pb-exposed mice were treated with D-mannose (2 g/kg) via daily oral gavage for two weeks. Control group animals were administered the same volume of sterile water following an identical schedule. D-mannose treatment restored the protein levels of ACSS2 (F (1, 20) = 51.84, p < 0.001) and p-ACSS2 (F (1, 20) = 8.746, p < 0.01) in Pb-exposed mice (Fig. 3D, E). The recovery of ACSS2 was accompanied by an increase in H3K9ac (F (1, 20) = 4.765, p < 0.05) (Fig. 3F). ELISA assays further showed that acetyl-CoA levels in the mPFC (F (1, 8) = 15.7, p < 0.01) and serum (F (1, 8) = 36.52, p < 0.001) of the Pb + D-mannose group were significantly higher than those in the Pb group (Fig. S3D-E). Behavioral assessments were conducted after the intervention (Fig. 1A). In the EPM, Pb + D-Man mice showed increased open arm entries (F (1, 36) = 4.687, p < 0.05) and dwell time (F (1, 36) = 6.399, p < 0.05) compared to Pb mice, reaching levels comparable to Ctrl (Fig. 3G-I). D-mannose also reduced immobility time in the TST (F (1, 36) = 26.29, p < 0.001) and FST (F (1, 36) = 114.9, p < 0.001) (Fig. 3J-M). HE staining showed that D-mannose alleviated Pb-induced neuronal abnormalities, with increased stained cells and ordered arrangement (Fig. 3N). Nissl staining showed increased Nissl body content and neuronal survival in D-mannose-treated mice (Fig. 3O). Augmentation of ACSS2 expression rescues pb-induced neuronal structural deficits in vitro To determine the appropriate Pb concentration for in vitro experiments, cells were exposed to a range of Pb concentrations (0, 1, 2.5, 5, 10, and 20 μM) for 48 h. Pb exposure at 5 μM did not significantly affect PC-12 cell viability (t (30) = 2.142, p > 0.05), whereas 10 μM (t (30) = 7.679, p < 0.001) and 20 μM (t (30) = 14.89, p < 0.001) Pb significantly reduced cell viability (Fig. S4). Therefore, 5 μM Pb was selected for subsequent in vitro experiments to model neurotoxic effects without confounding cytotoxicity. In Pb-exposed PC-12 cells, D-mannose (1 mM) restored ACSS2 (F (1, 20) = 31.77, p < 0.001), p-ACSS2 (F (1, 20) = 138.4, p < 0.001), and H3K9ac (F (1, 20) = 6.224, p < 0.05) levels (Fig. 4A-C). Immunofluorescence staining confirmed the recovery of nuclear ACSS2 and H3K9ac signals in D-mannose-treated cells (Fig. 4D-E). Cytoplasmic-nuclear fractionation showed that Pb exposure markedly reduced nuclear ACSS2 levels (F (1, 20) = 108.6, p < 0.001), with a less pronounced reduction in cytoplasmic ACSS2 (F (1, 20) = 14.58, p < 0.01). D-mannose treatment restored ACSS2 levels in both fractions in Pb-exposed cells (F (1, 20) = 91.55, p < 0.001), (F (1, 20) = 17.71, p < 0.001) (Fig. 3F-H). Acetyl-CoA levels in Pb-treated PC-12 cells were elevated following D-mannose supplementation (F (1, 8) = 6.846, p < 0.05) (Fig. S3F).Fig. 4Supplementation of ACSS2 agonist rescues pb-induced neuronal structural deficits in vitro. A representative western blot images and quantitative analysis of ACSS2, (B) p-ACSS2, and (C) H3K9ac in PC-12 cells. D representative immunofluorescence images of ACSS2 (red) and DAPI (blue) in PC-12 cells. Scale bar = 50 μm. E representative immunofluorescence images of H3K9ac (red) and DAPI (blue) in PC-12 cells. Scale bar = 50 μm. F—H representative western blot images and quantitative analysis of ACSS2 in the nucleus and cytoplasm of PC-12 cells. I representative images of NGF-differentiated PC-12 cells. Scale bar = 50 μm. J number of primary branches per cell. K number of secondary branches per cell. Sample sizes: For western blot analyses (A–C, F—H), n = 6 independent experiments; for immunofluorescence (D–E), images are representative of 3 independent experiments; for neurite outgrowth analysis (I—K), n = 30 cells from 6 independent experiments. Data are presented as mean ± SEM. Two-way ANOVA with Tukey's test was used for comparisons among the four groups (ctrl, pb, pb + D-man, D-man) (*p < 0.05; **p < 0.01; ***p < 0.001; ns, p > 0.05). (for interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)Fig. 4 Supplementation of ACSS2 agonist rescues pb-induced neuronal structural deficits in vitro. A representative western blot images and quantitative analysis of ACSS2, (B) p-ACSS2, and (C) H3K9ac in PC-12 cells. D representative immunofluorescence images of ACSS2 (red) and DAPI (blue) in PC-12 cells. Scale bar = 50 μm. E representative immunofluorescence images of H3K9ac (red) and DAPI (blue) in PC-12 cells. Scale bar = 50 μm. F—H representative western blot images and quantitative analysis of ACSS2 in the nucleus and cytoplasm of PC-12 cells. I representative images of NGF-differentiated PC-12 cells. Scale bar = 50 μm. J number of primary branches per cell. K number of secondary branches per cell. Sample sizes: For western blot analyses (A–C, F—H), n = 6 independent experiments; for immunofluorescence (D–E), images are representative of 3 independent experiments; for neurite outgrowth analysis (I—K), n = 30 cells from 6 independent experiments. Data are presented as mean ± SEM. Two-way ANOVA with Tukey's test was used for comparisons among the four groups (ctrl, pb, pb + D-man, D-man) (*p < 0.05; **p < 0.01; ***p < 0.001; ns, p > 0.05). (for interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) Pb exposure reduced the number of primary (F (1, 116) = 35.21, p < 0.001) and secondary (F (1, 116) = 34.49, p < 0.001) neurites in NGF-differentiated PC-12 cells. D-mannose treatment rescued the reduction in primary (F (1, 116) = 8.809, p < 0.01) and secondary (F (1, 116) = 21.85, p < 0.001) branches induced by Pb exposure. (Fig. 4I-K). ACSS2 activation restores synaptic protein expression, linking epigenetic regulation to synaptic function D-mannose-mediated ACSS2 augmentation reversed Pb-induced synaptic protein deficits. In vivo, D-mannose treatment upregulated GluN2A levels in Pb-exposed mice (F (1, 20) = 9.831, p < 0.01), VGLUT1 levels (F (1, 20) = 42.65, p < 0.001), and PSD95 levels (F (1, 20) = 60.64, p < 0.001) in the mPFC, reaching levels comparable to controls (Fig. 5A-C).Fig. 5Augmentation of ACSS2 rescues expression of synaptic-associated molecules. A Western blot analysis of GluN2A, (B) VGLUT1, and (C) PSD95 in the mPFC. D Western blot analysis of GluN2A, (E) VGLUT1, and (F) PSD95 in PC-12 cells. Sample sizes: For in vivo experiments (a–C), n = 6 offspring per group (randomly selected from 5 litters); for in vitro experiments (D—F), n = 6 independent experiments. Data are presented as mean ± SEM. Two-way ANOVA with Tukey's test was used for comparisons among the four groups (ctrl, pb, pb + D-man, D-man). (*p < 0.05; **p < 0.01; ***p < 0.001; ns, p > 0.05).Fig. 5 Augmentation of ACSS2 rescues expression of synaptic-associated molecules. A Western blot analysis of GluN2A, (B) VGLUT1, and (C) PSD95 in the mPFC. D Western blot analysis of GluN2A, (E) VGLUT1, and (F) PSD95 in PC-12 cells. Sample sizes: For in vivo experiments (a–C), n = 6 offspring per group (randomly selected from 5 litters); for in vitro experiments (D—F), n = 6 independent experiments. Data are presented as mean ± SEM. Two-way ANOVA with Tukey's test was used for comparisons among the four groups (ctrl, pb, pb + D-man, D-man). (*p < 0.05; **p < 0.01; ***p < 0.001; ns, p > 0.05). In vitro, Pb exposure reduced GluN2A, VGLUT1, and PSD95 levels in PC-12 cells. D-mannose co-treatment prevented this downregulation: GluN2A (F (1, 20) = 22.06, p < 0.001), VGLUT1 (F (1, 20) = 22.92, p < 0.001), and PSD95 (F (1, 20) = 13.21, p < 0.01) were all restored to levels comparable to controls (Fig. 5D-F). The AMPK-ACSS2 signaling pathway positively regulates pb-induced neurotoxicity We first examined whether Pb exposure affects AMPK expression. In vivo, AMPK protein levels in the mPFC of Pb-exposed mice were significantly lower than those in the Ctrl group (t (10) = 3.074, p < 0.05) (Fig. 6A); no significant difference was observed in the hippocampus (t (10) = 0.2615, p > 0.05) (Fig. S2C). In vitro, AMPK protein expression in Pb-exposed PC-12 cells was downregulated compared to the Ctrl group (t (10) =4.231, p < 0.01) (Fig. 6B).Fig. 6The AMPK-ACSS2 signaling pathway positively regulates pb-induced neurotoxicity. A Western blot analysis of AMPK in the mPFC. B Western blot analysis of AMPK in PC-12 cells. C Western blot analysis of AMPK in PC-12 cells (AICAR intervention). D Western blot analysis of ACSS2 in PC-12 cells (AICAR intervention). E Western blot analysis of p-ACSS2 in PC-12 cells (AICAR intervention). F representative images of NGF-differentiated PC-12 cells. Scale bar = 50 μm. G quantitative analysis of p-ACSS2 protein expression in PC-12 cells. H number of primary branches per cell. I number of secondary branches per cell. Sample sizes: For in vivo experiments (A), n = 6 offspring per group (randomly selected from 5 litters); for in vitro experiments (B–E, G), n = 6 independent experiments; for neurite outgrowth analysis (F, H—I), n = 30 cells from 6 independent experiments. Data are presented as mean ± SEM. Two-way ANOVA with Tukey's test was used for comparisons among the four groups (ctrl, pb, pb + AICAR, AICAR); unpaired t-test was used for two-group comparisons. (*p < 0.05; **p < 0.01; ***p < 0.001; ns, p > 0.05).Fig. 6 The AMPK-ACSS2 signaling pathway positively regulates pb-induced neurotoxicity. A Western blot analysis of AMPK in the mPFC. B Western blot analysis of AMPK in PC-12 cells. C Western blot analysis of AMPK in PC-12 cells (AICAR intervention). D Western blot analysis of ACSS2 in PC-12 cells (AICAR intervention). E Western blot analysis of p-ACSS2 in PC-12 cells (AICAR intervention). F representative images of NGF-differentiated PC-12 cells. Scale bar = 50 μm. G quantitative analysis of p-ACSS2 protein expression in PC-12 cells. H number of primary branches per cell. I number of secondary branches per cell. Sample sizes: For in vivo experiments (A), n = 6 offspring per group (randomly selected from 5 litters); for in vitro experiments (B–E, G), n = 6 independent experiments; for neurite outgrowth analysis (F, H—I), n = 30 cells from 6 independent experiments. Data are presented as mean ± SEM. Two-way ANOVA with Tukey's test was used for comparisons among the four groups (ctrl, pb, pb + AICAR, AICAR); unpaired t-test was used for two-group comparisons. (*p < 0.05; **p < 0.01; ***p < 0.001; ns, p > 0.05). To directly test whether AMPK regulates ACSS2, we performed intervention studies using the AMPK agonist AICAR. Four groups were established: Ctrl, Pb, Pb + AICAR, and AICAR. AICAR treatment restored AMPK activity (F (1, 20) = 7.432, p < 0.05) and reversed Pb-induced reductions in both total ACSS2 (F (1, 20) = 5.609, p < 0.05) and p-ACSS2 (F (1, 20) = 7.023, p < 0.05) (Fig. 6C-E, G). AICAR treatment also rescued Pb-impaired neuronal branching complexity, restoring primary (F (1, 116) = 4.145, p < 0.05) and secondary (F (1, 116) = 4.827, p < 0.05) branch numbers to control levels (Fig. 6F, H-I). Discussion In this study, we tested the hypothesis that developmental Pb exposure induces anxiety and depression-like behaviors through epigenetic dysregulation mediated by the AMPK/ACSS2 pathway. Our findings demonstrate that Pb exposure suppresses AMPK activity, leading to reduced ACSS2 expression and nuclear translocation, which in turn diminishes acetyl-CoA availability and histone H3K9 acetylation. These epigenetic alterations are associated with downregulation of key synaptic proteins (GluN2A, VGLUT1, PSD-95) and neuronal structural damage in the mPFC, ultimately resulting in anxiety and depression-like behaviors. Importantly, pharmacological activation of ACSS2 with D-mannose restored ACSS2 function, reversed the epigenetic and synaptic deficits, and alleviated the behavioral abnormalities, identifying ACSS2 as a critical node in Pb neurotoxicity. Furthermore, using the AMPK agonist AICAR, we confirmed that AMPK acts as an upstream regulator of ACSS2 in this context. Collectively, these findings establish the AMPK/ACSS2 signaling pathway as a core mechanism linking Pb exposure to affective disorders and highlight ACSS2 augmentation as a potential therapeutic strategy. Epidemiological and animal studies have consistently identified the nervous system as a highly sensitive tissue to Pb exposure (Vivier et al., 2011; Bouchard et al., 2009). Recent epidemiological evidence further reveals a significant positive association between childhood Pb exposure and adult anxiety and depression: each 10 μg/dL increase in blood Pb is linked to an 18% higher risk of depression, and individuals with blood Pb > 2.1 μg/dL have a 2.3-fold greater likelihood of major depressive disorder (Orisakwe, 2014; Li et al., 2017b; Wu et al., 2018). To model this environmentally relevant exposure, we employed a developmental Pb exposure paradigm beginning at gestational day 0 (GD 0, plug day) and continuing through PND 60. Pregnant dams were randomly assigned to four groups (Ctrl, Pb, Pb + D-Man, D-Man; n = 5 dams per group), and Pb exposure (100 ppm in drinking water) was maintained from GD 0 until weaning (PND 21) via maternal exposure, followed by direct offspring exposure from PND 21 to PND 60. This exposure recapitulated the long-term emotional deficits observed epidemiologically, supporting a developmental programming effect of early-life Pb neurotoxicity. Given the central role of epigenetic dysregulation in environmentally induced depression, we investigated whether histone acetylation is a target of Pb neurotoxicity. Studies have confirmed that Pb can disrupt multiple epigenetic modifications to contribute to neural damage, such as histone methylation (Gu et al., 2019), histone acetylation (Wang et al., 2022), and DNA methylation (Zhao et al., 2025). We next sought to identify the enzymes responsible for the acetyl-CoA deficiency. Our results showed that Pb exposure selectively downregulated ACSS2, but not ACSS1, in the mPFC. To determine whether restoring ACSS2 activity could reverse Pb-induced deficits, we performed an in vivo rescue experiment using the ACSS2 agonist D-mannose. D-mannose treatment restored ACSS2 and p-ACSS2 levels, increased H3K9ac, elevated acetyl-CoA levels, reversed Pb-induced anxiety- and depression-like behaviors, and alleviated neuronal morphological damage. These findings confirm that ACSS2 activation restores the synaptic molecular environment disrupted by Pb exposure. Acetyl-CoA is a core intermediate in cellular metabolic networks, and its homeostasis is crucial for maintaining normal cellular physiological functions (Guertin and Wellen, 2023; Gout, 2018). In the cytoplasm, ACSS2 is the key enzyme for acetyl-CoA synthesis (Hao et al., 2022; Li et al., 2021b); nuclear-localized ACSS2 maintains nuclear acetyl-CoA homeostasis and provides direct substrates for histone acetylation. To further validate the neuroprotective effects of ACSS2 augmentation at the cellular level, we employed an in vitro PC-12 neuronal model. Our in vitro findings demonstrated that ACSS2 augmentation reverses Pb-induced molecular and cellular damage by restoring acetyl-CoA synthesis, upregulating histone acetylation, and improving neuronal morphology. Specifically, D-mannose restored ACSS2, p-ACSS2, and H3K9ac levels in Pb-exposed PC-12 cells, promoted nuclear accumulation of ACSS2, and rescued Pb-impaired neurite outgrowth. This mechanism underpins the anxiolytic and antidepressant effects of ACSS2 augmentation observed in behavioral experiments. We next explored the downstream consequences of ACSS2 deficiency, focusing on synaptic molecules involved in emotional regulation. Our results showed that D-mannose-mediated ACSS2 augmentation reversed Pb-induced synaptic protein deficits both in vivo and in vitro, upregulating GluN2A, VGLUT1, and PSD95 to control levels. Synaptic plasticity is highly sensitive to environmental stress (Moses-Kolko et al., 2014; Bragazzi et al., 2023), and these synaptic proteins are key regulators of glutamatergic transmission. Pb exposure impairs these markers (Zhang et al., 2021), and restoring them may ameliorate behavioral deficits. Given that AMPK is a well-established upstream kinase that regulates ACSS2 activity, we further investigated its role in Pb-induced ACSS2 dysfunction. AMPK regulates ACSS2 activity and subcellular localization through phosphorylation (Chen et al., 2024; Zlotorynski, 2017; Izzo et al., 2021; Li et al., 2022). Consistent with this, we found that Pb exposure inhibited AMPK expression in both the mPFC and PC-12 cells. Using the AMPK agonist AICAR, we demonstrated that AICAR treatment restored AMPK activity, reversed Pb-induced reductions in ACSS2 and p-ACSS2, and rescued Pb-impaired neuronal branching complexity, confirming AMPK as an upstream regulator of ACSS2. Limitations Several limitations of this study should be acknowledged. First, detailed maternal parameters during gestation, such as maternal body weight changes, food consumption, and gestational length, were not systematically recorded. Second, we did not assess stillbirth rates in detail. Third, food and water consumption were not systematically measured during the post-weaning period, which may have provided additional insights into Pb exposure levels. Fourth, we cannot exclude potential maternal behavioral changes (e.g., nursing) that were not assessed. Future cross-fostering studies could dissect prenatal versus postnatal Pb contributions. Fifth, this study only examined the short-term behavioral effects of ACSS2 augmentation, as behavioral tests were performed immediately after the two-week D-mannose treatment. The long-term durability of these effects remains unknown. Future studies should assess whether ACSS2 activation produces sustained benefits weeks after treatment cessation and whether repeated dosing is required. Nevertheless, several observations indicate that the Pb exposure paradigm (100 ppm in drinking water) did not cause overt maternal toxicity or gross developmental abnormalities: (i) no maternal deaths occurred during the study; (ii) water consumption did not differ between Pb-exposed and control dams (Supplementary Table S1); (iii) delivery occurred on GD 19–20 in all dams, with no significant difference among groups; (iv) litter sizes ranged from 4 to 6 pups per litter with a roughly balanced sex ratio across groups, and no stillbirths or morphological abnormalities were observed; (v) offspring body weight trajectories from PND 7 to PND 81 did not differ among groups (Supplementary Fig. S1); and (vi) during lactation (PND 0–21), offspring were exposed to Pb only indirectly through maternal milk, as they had no direct access to drinking water until weaning. Future studies should incorporate comprehensive monitoring of gestational, lactational, and post-weaning parameters to further dissect the contributions of gestational versus postnatal Pb exposure to neurobehavioral deficits. Conclusion In this study, we investigated the contribution of chronic Pb exposure to anxiety and depression-like behaviors and elucidated the critical role of ACSS2 in the underlying pathogenesis. Our findings demonstrate that Pb exposure disrupts the AMPK-ACSS2 signaling pathway, leading to impaired histone acetylation, downregulation of key synaptic molecules, and ultimately, the manifestation of emotional disorders. Crucially, specific pharmacological augmentation of ACSS2 effectively ameliorated these behavioral deficits. Our work is the first to identify the AMPK/ACSS2 signaling pathway as a core regulator in Pb-induced neurotoxicity, highlighting ACSS2 augmentation as a promising novel strategy for preventing and treating Pb-related emotional disorders. Author contribution Mengqin Tao: Methodology, Investigation, Validation, Writing-original draft, Formal analysis. Shu Ai: Methodology, Investigation, Writing- review & editing. Mengmeng Wang: Methodology, Investigation. Xiaozhen Gu: Funding acquisition, Writing- review & editing. Mingli Sun: Investigation, Validation. Hui-Li Wang: Supervision, Conceptualization, Funding acquisition, Writing- review & editing. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.